FINWIRES · TerminalLIVE
FINWIRES

Pitney Bowes Q2 Adjusted Earnings Rise, Revenue Falls; Raises 2026 Adjusted EPS Guidance

By

Pitney Bowes (PBI) reported Q2 adjusted earnings Wednesday of $0.43 per diluted share, up from $0.27 a year earlier.

Analysts polled by FactSet expected $0.34.

Revenue for the quarter ended June 30 was $451.5 million, compared with $461.9 million a year earlier.

Four analysts expected $453.9 million.

For 2026, the company said it now expects adjusted EPS of $1.55 to $1.70, up from its prior guidance of $1.50 to $1.65. Analysts are looking for $1.62.

Shares of the company were up over 5% in Thursday premarket activity.

Price: $18.57, Change: $+0.91, Percent Change: +5.15%

Related Articles

Wire

Houlihan Lokey Fiscal Q1 Adjusted Earnings, Revenue Fall; Shares Drop After Hours

Houlihan Lokey (HLI) reported fiscal Q1 adjusted earnings late Wednesday of $1.35 per diluted share, down from $2.14 a year earlier.Analysts polled by FactSet expected $1.64.Revenue in the three months ended June 30 fell to $511 million from $605 million a year earlier.Analysts expected $602.4 million.Houlihan Lokey shares fell 6.6% in after-hours trading.

$HLI
Wire

Four Corners Property Trust Q2 AFFO, Revenue Rise

Four Corners Property Trust (FCPT) reported Q2 adjusted funds from operations late Wednesday of $0.45 per diluted share, up from $0.44 a year earlier.Analysts polled by FactSet expected $0.45.Revenue in the quarter ended June 30 rose to $78.4 million from $72.8 million a year earlier.Four analysts expected $79 million.The company's shares rose 2% in after-hours trading.

$FCPT
Wire

Corcept Therapeutics Q2 Earnings, Revenue Rise; Shares Jump After Hours

Corcept Therapeutics (CORT) reported Q2 earnings late Wednesday of $0.36 per diluted share, up from $0.29 a year earlier.Analysts polled by FactSet expected $0.02.Revenue for the three months ended June 30 rose to $256.1 million from $194.4 million a year earlier.Analysts expected $221.1 million.The company boosted full-year revenue guidance to $1.1 billion to $1.2 billion from the prior forecast of $950 million to $1.05 billion.Analysts project $999.5 million.Corcept shares jumped 18% in after-hours trading.

$CORT